Table 2 Study sample clinical characteristics (n=35)
From: Real-World experience of interictal burden and treatment in migraine: a qualitative interview study
Sample characteristic | Statistic | |
|---|---|---|
Migraine days per month (last three months) Mean (SD) | 12.1 (8.0) | |
Age at diagnosis Mean (SD) | 26.5 (14.0) | |
Type of migraine N (%) | ||
Chronic migraine | 13 (37%) | |
Migraine with aura a | 9 (26%) | |
Other migraine subtype b | 8 (23%) | |
Don’t know | 9 (26%) | |
Other long-term conditions | ||
Anxiety | 18 (51%) | |
Bipolar disorder | 1 (3%) | |
Depression | 12 (34%) | |
Diabetes | 2 (6%) | |
Fibromyalgia | 4 (11%) | |
Hypertension | 3 (9%) | |
Post-traumatic stress disorder | 2 (6%) | |
Respiratory condition | 4 (11%) | |
Other | 6 (17%) | |
None | 11 (31%) | |
Acute Treatments | ||
Drug Type | Current/Most Recent Treatment | (All) Past Treatments |
Pain relievers | 15 (43%) | 14 (40%) |
Triptans | 18 (51%) | 14 (40%) |
Anti-nausea drugs | 1 (3%) | 1 (3%) |
Other | 4 (11%) | 3 (9%) |
Preventive Treatments | ||
Drug Type | Current/Most Recent Treatment | (All) Past Treatments |
Anti-epileptics | 8 (23%) | 14 (40%) |
Anti-depressants | 2 (6%) | 14 (40%) |
Beta-blockers | 2 (6%) | 13 (37%) |
Neurotoxins (Botox) | 4 (11%) | 6 (17%) |
Calcium channel blockers | – | 1 (3%) |
Angiotensin receptor blockers | – | 3 (9%) |
CGRP mAbs | 7 (20%) a | 8 (23%) b |
Other | 3 (9%) | 1 (3%) |